ChemicalBook > Product Catalog >API >Digestive system drugs >Antacid and Mucosal protective Drugs >R-(+)-Lansoprazole


R-(+)-Lansoprazole Suppliers list
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Products Intro: Product Name:138530-94-6
Purity:0.99 Package:25KG,5KG;1KG;500G
Tel: +86 21 5161 9050/ 5187 7795
Products Intro: Product Name:(R)-Lansoprazole
Purity:98% HPLC Package:5G;10G;25G;50G;100G;250G;1KG
Company Name: career henan chemical co
Tel: +86-371-86658258
Products Intro: Product Name:R-(+)-Lansoprazole
Purity:98% Package:1KG;200USD
Company Name: Hubei Jusheng Technology Co.,Ltd.
Tel: 86-18871470254
Products Intro: Product Name:R-(+)-Lansoprazole
Purity:99% Package:5KG;1KG Remarks:C16H14F3N3O2S
Company Name: Casorganics US Corp
Tel: +17326109938
Products Intro: Product Name:R-(+)-Lansoprazole
Purity:99.98% Package:1KG;USD|5KG;USD|25KG;USD

Lastest Price from R-(+)-Lansoprazole manufacturers

  • R-(+)-Lansoprazole
  • US $1.00-1.00 / Kg/Bag
  • 2020-05-12
  • CAS:138530-94-6
  • Min. Order: 1g
  • Purity: 99%
  • Supply Ability: 50tons
  • R-(+)-Lansoprazole
  • US $200.00 / KG
  • 2019-07-06
  • CAS:138530-94-6
  • Min. Order: 100G
  • Purity: 98%
  • Supply Ability: 200KG
R-(+)-Lansoprazole Basic information
Product Name:R-(+)-Lansoprazole
Synonyms:Lansoprazole Impurity 14;Dexlansoprazole related impurities 2;(R)-2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole;1H-Benzimidazole, 2-[(R)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI);1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-, (R)-;R-(+)-Lansoprazole;Dexlansoprazole;2-[(R)-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
Product Categories:DEXILANT;APIs;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
Mol File:138530-94-6.mol
R-(+)-Lansoprazole Structure
R-(+)-Lansoprazole Chemical Properties
Melting point 66-68?C
Boiling point 555.8±60.0 °C(Predicted)
density 1.50±0.1 g/cm3(Predicted)
storage temp. Refrigerator
Safety Information
MSDS Information
R-(+)-Lansoprazole Usage And Synthesis
DescriptionThe mechanism of PPIs involves the irreversible binding to the hydrogen/potassium adenosine triphosphatase enzyme system, commonly referred to as the gastric proton pump, of the gastric parietal cell. As the last stage in gastric acid secretion, blockade of the gastric proton pump is an effective treatment for a variety of diseases requiring acid suppression, such as heartburn, peptic ulcers, and GERD. Dexlansoprazole is the latest PPI to hit the market, joining the ranks of omeprazole, rabeprazole, pantoprazole, esomeprazole, and lansoprazole, and is the Renantiomer of the racemic lansoprazole. Compared to its predecessors, dexlansoprazole exhibits improved pharmacokinetics with slower clearance and longer terminal half-life. In addition, dexlansoprazole utilizes a novel DDR technology; drug release is optimized through the use of granules with different pH-dependent dissolution profiles, thereby providing an initial release in the proximal small intestine within 1-2 h of administration followed by a subsequent release at distal regions of the small intestine several hours later. With its longer duration of action culminating in more effective acid suppression, dexlansoprazole may have an advantage over conventional PPIs that possess single release formulations (immediate or delayed). Similar to all PPIs, dexlansoprazole is a prodrug that consists of pyridine and benzimidazole rings with a latent sulfenamide moiety. In order to form the disulfide bond with cysteine residues of the proton pump, dexlansoprazole must be activated through two protonations followed by a spontaneous rearrangement to unmask the sulfenamide.
Chemical PropertiesBrown Solid
OriginatorTakeda (Japan)
UsesThe R-enantiomer of Lansoprazole; a gastric proton pump inhibitor. An antiulcerative
Usesantiulcer, proton pump inhibitor
UsesActs as a gastric proton pump inhibitor and an antiulcerative
Brand nameKapidex
Side effectsThe most commonly recorded adverse reactions that occurred at a higher incidence than placebo were diarrhea, abdominal pain, nausea, vomiting, flatulence, and upper respiratory tract infection. As dexlansoprazole inhibits gastric acid secretion, its use is expected to interfere with the absorption of drugs with pH-dependent oral bioavailability. Since the HIV protease inhibitor atazanavir is dependent on gastric acid for absorption, dexlansoprazole should not be co-administered with atazanavir to avoid a loss of therapeutic efficacy. While co-administration of dexlansoprazole did not affect the pharmacokinetics of warfarin or INR (international normalized ratio: the ratio of a patient s prothrombin time to a normal sample), there have been reports of increased INR and prothrombin time in patients receiving concomitant treatment with PPIs and warfarin. Since increases in INR and prothrombin time may lead to abnormal bleeding and possibly death, concomitant use of dexlansoprazole and warfarin may necessitate monitoring for increases in INR and prothrombin time.
R-(+)-Lansoprazole Preparation Products And Raw materials
Tag:R-(+)-Lansoprazole(138530-94-6) Related Product Information
Lansoprazole N-Oxide Lansoprazole Sulfone N-Oxide 2-[[[4-(2,2,2-Trifluoroethoxy)-3-Methyl-1-oxopyridin-2-yl]Methyl]sulfanyl]-1H-benziMidazole LANSOPRAZOLE SULFONE N-[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl Lansoprazole Sulfide 1-Methyl-12-thioxopyrido[1,2,3,4]imidazole-[1,2-a]benzimidazole-2(12H)-one Entacapone Exemestane Azelnidipine Tenofovir Imatinib mesylate Stavudine Zidovudine Rabeprazole Pantoprazole Omeprazole Lansoprazole